Our Board

OpenBioSim is a Community Interest Company — a not-for-profit organisation. Any surplus we generate is reinvested into research, open-source software, and community activities. The board ensures that our operations remain aligned with the mission of the company.

  • Julien Michel

    Julien Michel

    Managing Director, OpenBioSim. Professor of Biomolecular Simulation, University of Edinburgh.

    Julien has over 20 years experience in academic research in molecular stimulation methodologies and their applications in biosciences. He has an extensive track-record of collaborative research and open source software development with the pharmaceutical industry and academic communities.

  • Christopher Woods

    Consultant, OpenBioSim. Al Supercomputing Infrastructure Lead, University of Bristol.

    Christopher began his career as a computational chemist, spending ~15 years developing new software and new algorithms for predicting biomolecular free energies. He currently is AI Supercomputing Infrastructure Lead at the University of Bristol, where he helps run the Isambard-AI national facility. He holds a Catalyst award for his help in establishing and growing the Society of Research Software Engineering.

  • Mark Mackey

    Founder and Chief Scientific Officer, Cresset

    Mark has been working in computational methods development for more than 25 years and is responsible for the Cresset scientific research team as well as guiding the software development process at Cresset.

  • Ben Cossins

    Director of Computational Drug Design, Peptone

    Ben has over 20 years of experience of modelling in academia and industry. A specialism in the use of molecular simulation to optimise small molecule drugs and find their targets has taken up the majority of his time.

  • Charles Laughton

    Professor of Computational Pharmaceutical Science, University of Nottingham

    Charlie has more than 30 years experience in Computational Modelling and Informatics, primarily related to Biomolecular science and Drug Discovery and Development. He focuses particularly on the development of software tools for data analysis and validation, and for high-throughput and high-performance computing.